Hyperuricemia Medical Services in China

Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid (SUA) levels—defined as >6.8 mg/dL (>405 µmol/L) in adults—beyond the physiological saturation threshold for monosodium urate crystallization. It arises from an imbalance between uric acid production and excretion, primarily driven by impaired renal urate clearance (accounting for ~90% of cases) or, less commonly, overproduction due to purine metabolism dysregulation (e.g., PRPS1 mutations, HGPRT deficiency, or high-purine diets). Pathophysiologically, hyperuricemia triggers low-grade systemic inflammation via NLRP3 inflammasome activation, endothelial dysfunction, oxidative stress, and renin-angiotensin system upregulation—linking it mechanistically to hypertension, chronic kidney disease (CKD), insulin resistance, cardiovascular disease, and gout. Epidemiologically, prevalence has risen globally alongside urbanization and dietary shifts: current estimates indicate ~14–24% of adults in China have hyperuricemia, with higher rates among men (20–30%) than women (10–15%), and sharp increases after age 40. Key modifiable risk factors include obesity (especially abdominal adiposity), excessive alcohol intake (particularly beer and spirits), high-fructose beverages, red meat and seafood consumption, diuretic use (e.g., thiazides), chronic kidney disease, metabolic syndrome, and hypothyroidism. Non-modifiable risks include male sex, aging, genetic predisposition (e.g., SLC2A9, ABCG2 variants), and familial history. Importantly, hyperuricemia is often asymptomatic for years—yet persistent elevation (>7 mg/dL) significantly increases lifetime gout risk (up to 20% at 5 years, >50% at 20 years) and accelerates CKD progression. Beyond physical morbidity, it substantially impairs quality of life: patients report fatigue, joint stiffness, sleep disruption, anxiety about gout flares, reduced work productivity, dietary restrictions causing social isolation, and long-term concerns about kidney failure or cardiovascular events. Early detection and individualized management—including lifestyle modification, uricosurics (e.g., benzbromarone), or xanthine oxidase inhibitors (e.g., febuxostat, allopurinol)—are critical not only to prevent gout but also to mitigate multisystem end-organ damage. Rheumatology and immunology departments play a central role in diagnosis, risk stratification (e.g., 24-hour urinary uric acid testing, renal function assessment), and longitudinal care, especially given the frequent comorbidity with autoimmune rheumatic diseases such as psoriatic arthritis and lupus nephritis.

Hyperuricemia is defined as an elevated serum uric acid concentration exceeding 6.8 mg/dL—the physiological saturation point at which monosodium urate crystals may precipitate in tissues. It arises from an imbalance between uric acid production and excretion, with approximately 90% of cases attributable to underexcretion by the kidneys and 10% to overproduction. Common causes include chronic kidney disease (CKD), particularly stages 3–5, where reduced glomerular filtration rate impairs urate clearance; metabolic syndrome components such as insulin resistance, obesity, and hypertension, which promote renal sodium and urate reabsorption via upregulation of URAT1 and SLC2A9 transporters; and diuretic use—especially thiazides and loop diuretics—which induce volume depletion and enhance proximal tubular urate reabsorption. Other pharmacologic causes include low-dose aspirin (<2 g/day), which inhibits renal urate secretion; cyclosporine and tacrolimus, which reduce renal blood flow and tubular secretion; and niacin (vitamin B3) at pharmacologic doses, which interferes with hepatic xanthine oxidase regulation.

Triggers of acute hyperuricemia exacerbation include rapid cell turnover states—e.g., tumor lysis syndrome following chemotherapy for hematologic malignancies, rhabdomyolysis, or severe hemolysis—leading to massive purine catabolism and uric acid generation. Acute alcohol ingestion, particularly beer and spirits (but not wine in moderation), increases uric acid synthesis via ATP depletion and lactate accumulation, which competitively inhibits urate excretion. Dehydration, fasting, ketogenic diets, and high-intensity exercise can also transiently elevate serum urate through hemoconcentration, ketosis-induced competition for organic anion transport, or muscle breakdown.

Established risk factors encompass age (prevalence rises after age 40 in men and postmenopausal women), male sex (premenopausal estrogen enhances uricosuria), obesity (adipose tissue releases proinflammatory cytokines that impair renal urate handling and promotes insulin resistance), hypertension (often associated with renin-angiotensin-aldosterone system activation and reduced renal perfusion), and type 2 diabetes mellitus (hyperinsulinemia directly stimulates URAT1-mediated urate reabsorption). Chronic heart failure and obstructive sleep apnea are increasingly recognized comorbidities linked to intermittent hypoxia-induced xanthine oxidase upregulation and oxidative stress.

Genetic factors contribute significantly to interindividual variability in uric acid homeostasis. Polymorphisms in solute carrier genes—including SLC2A9 (GLUT9), SLC22A12 (URAT1), and ABCG2 (BCRP)—account for up to 7% of serum urate variance. Loss-of-function variants in ABCG2 (e.g., Q141K) markedly reduce gut urate excretion and are strongly associated with early-onset gout and tophaceous disease. SLC2A9 variants influence both renal reabsorption and extrarenal handling, with sex-specific effects (greater impact in women). Rare monogenic disorders include hereditary renal hypouricemia (SLC22A12 mutations), PRPS superactivity (PRPS1 gain-of-function), and HPRT deficiency (Lesch-Nyhan syndrome), all causing profound uric acid dysregulation. Genome-wide association studies have identified over 30 loci associated with serum urate levels, underscoring polygenic inheritance patterns.

Environmental factors modulate genetic susceptibility. Dietary purine load—particularly from red meat, organ meats, shellfish, and sugar-sweetened beverages containing fructose—is a major modifiable contributor: fructose metabolism depletes intracellular phosphate, stimulating AMP degradation and uric acid synthesis. High sodium intake may paradoxically increase uricosuria in some individuals but exacerbates hypertension-related renal impairment in others. Urban living, sedentary lifestyle, and socioeconomic determinants—including limited access to fresh produce and healthcare—correlate with higher prevalence. Environmental pollutants such as lead exposure (historical or occupational) cause chronic interstitial nephritis and impaired urate excretion. Smoking has complex associations: while nicotine may modestly lower uric acid acutely, chronic smoking contributes to endothelial dysfunction and CKD progression, indirectly promoting hyperuricemia. Climate extremes—especially hot, humid environments—predispose to dehydration and concentrated urine, facilitating crystal formation. Collectively, hyperuricemia reflects a multifactorial convergence of renal physiology, metabolic dysregulation, genetic architecture, and environmental exposures—making it a key biomarker and therapeutic target in rheumatology and systemic inflammatory disease management.

Hyperuricemia is defined as a serum uric acid concentration exceeding 6.8 mg/dL (405 µmol/L) — the physiological saturation threshold at which monosodium urate (MSU) crystals can precipitate in tissues. While often asymptomatic, it serves as the biochemical substrate for gout, uric acid nephrolithiasis, and chronic uric acid nephropathy, and is increasingly recognized as an independent risk factor for cardiovascular and metabolic comorbidities. In the Department of Rheumatology and Immunology, hyperuricemia is evaluated not merely as a laboratory abnormality but as a systemic disorder with multisystem implications.

Early symptoms are typically absent; most individuals with asymptomatic hyperuricemia remain clinically silent for years or decades. However, subtle prodromal signs may emerge in predisposed individuals, including intermittent, non-inflammatory joint discomfort—often misattributed to overuse or early osteoarthritis—particularly in the first metatarsophalangeal (MTP) joint, midfoot, or distal interphalangeal joints. Some patients report recurrent episodes of mild, self-limiting swelling or stiffness lasting <24 hours, without classic inflammatory features (erythema, warmth, marked tenderness), suggesting subclinical crystal deposition or microcrystal-induced low-grade synovial activation. Fatigue, mild cognitive fog, or nonspecific musculoskeletal aches may also occur, though these lack diagnostic specificity and are frequently overlooked.

Typical symptoms manifest only upon transition to symptomatic disease—most commonly acute gouty arthritis. This presents as a sudden, severe, monoarticular inflammatory arthropathy, classically involving the first MTP joint (podagra), but also affecting the ankle, knee, midtarsal joints, wrist, or fingers. The onset is often nocturnal, with rapid progression to intense pain, exquisite tenderness, swelling, erythema, and functional impairment within hours. The affected joint appears warm, shiny, and exquisitely sensitive—even light touch (e.g., bedsheet pressure) may be intolerable. Attacks typically peak within 24–48 hours and resolve spontaneously over 7–14 days if untreated. Recurrent attacks become more frequent, prolonged, and polyarticular over time. Tophaceous gout develops after years of uncontrolled hyperuricemia, characterized by visible, firm, chalky, yellowish-white subcutaneous nodules—commonly over the helix of the ear, olecranon bursa, Achilles tendon, or finger extensor surfaces. These tophi may ulcerate, discharge chalky material, and cause local bone erosion visible on radiography as punched-out lytic lesions with overhanging edges.

Accompanying symptoms reflect systemic inflammation and comorbidity burden. Patients frequently exhibit features of metabolic syndrome: central obesity, hypertension (often resistant), fasting hyperglycemia or type 2 diabetes mellitus, and dyslipidemia (elevated triglycerides, low HDL). Nephrological manifestations include asymptomatic microscopic hematuria, mild proteinuria (<1 g/day), or reduced estimated glomerular filtration rate (eGFR) without overt renal failure. Some report postprandial flank discomfort or dull, persistent lower back ache—possibly reflecting chronic urate crystal deposition in renal interstitium or early obstructive uropathy. Uric acid kidney stones may present with colicky flank pain, hematuria, dysuria, or recurrent urinary tract infections; however, up to 30% of uric acid calculi are radiolucent on plain abdominal X-ray, necessitating ultrasound or non-contrast CT for detection.

Complications arise from persistent crystal deposition and chronic inflammation. Chronic tophaceous gout leads to irreversible joint destruction, deformity, and disability. Urate nephropathy progresses to chronic kidney disease (CKD), with hyperuricemia independently associated with accelerated eGFR decline, particularly in patients with preexisting hypertension or diabetes. Acute uric acid nephropathy—a medical emergency—occurs in tumor lysis syndrome or rhabdomyolysis, causing rapid oliguric or anuric renal failure due to intratubular uric acid crystal precipitation. Cardiovascular complications include increased risk of hypertension, coronary artery disease, heart failure, and ischemic stroke—mechanistically linked to endothelial dysfunction, oxidative stress, renin-angiotensin system activation, and vascular smooth muscle proliferation induced by uric acid. Emerging evidence also links hyperuricemia to nonalcoholic fatty liver disease (NAFLD), insulin resistance, and subclinical atherosclerosis.

Diagnosis relies on quantitative serum uric acid measurement, ideally performed after an overnight fast and avoiding recent purine-rich meals, alcohol, or diuretics. A single elevated value warrants confirmation after ≥2 weeks, as levels fluctuate diurnally and with hydration status. Synovial fluid analysis remains the gold standard for diagnosing acute gout: compensated polarized light microscopy reveals negatively birefringent, needle-shaped MSU crystals within neutrophils. Dual-energy CT (DECT) is highly specific for detecting urate deposits in joints and soft tissues—even—and quantifies total body urate burden. Ultrasound demonstrates the 'double contour sign' (hyperechoic band over cartilage surface) and tophi with high sensitivity. Renal imaging includes non-contrast CT for stone detection and renal ultrasound for parenchymal echogenicity, hydronephrosis, or structural abnormalities. Urinary uric acid excretion (24-hour collection) helps classify hyperuricemia as overproduction (>800 mg/day on unrestricted diet) or underexcretion (<600 mg/day), guiding targeted therapy.

Differential diagnosis is critical to avoid misattribution. Septic arthritis must be excluded emergently—fever, leukocytosis, and markedly elevated CRP/ESR may overlap, but synovial fluid WBC >50,000/µL with positive culture confirms infection. Pseudogout (calcium pyrophosphate deposition disease) mimics gout clinicallyingent rhomboid crystals on microscopy and chondrocalcinosis on X-ray. Rheumatoid arthritis presents with symmetric, erosive, small-joint polyarthritis and seropositivity (RF, anti-CCP); imaging shows periarticular osteopenia and marginal erosions—not the 'punched-out' lesions of tophaceous gout. Reactive arthritis may follow gastrointestinal or genitourinary infections and features dactylitis, enthesitis, and conjunctivitis. Psoriatic arthritis often involves distal interphalangeal joints, nail pitting, and dactylitis, with characteristic 'pencil-in-cup' radiographic changes. Osteoarthritis causes gradual, activity-related joint pain without acute inflammation; radiographs show joint space narrowing and osteophytes, not tophi or crystal-induced erosions. Finally, cellulitis or deep vein thrombosis may mimic acute gout clinically but lacks intra-articular involvement and shows distinct imaging findings. Accurate differentiation requires integrated assessment of clinical phenotype, laboratory biomarkers, imaging, and—if indicated—synovial fluid analysis.

Hyperuricemia—a serum uric acid concentration exceeding 6.8 mg/dL (405 µmol/L) in men and postmenopausal women, or 5.7 mg/dL (340 µmol/L) in premenopausal women—is a metabolic disorder characterized by impaired purine metabolism or reduced renal urate excretion. While often asymptomatic, persistent hyperuricemia is the biochemical prerequisite for gout, uric acid nephrolithiasis, chronic kidney disease (CKD), and cardiovascular morbidity. Management in the Department of Rheumatology and Immunology emphasizes risk stratification: asymptomatic individuals require intervention only if serum uric acid exceeds 9.0 mg/dL, or if comorbidities such as hypertension, CKD stage ≥2, diabetes mellitus, or cardiovascular disease are present. Treatment goals include sustained serum uric acid reduction to <6.0 mg/dL (or <5.0 mg/dL in patients with tophaceous gout or frequent flares), prevention of crystal deposition, and mitigation of systemic inflammatory sequelae.

Conservative treatment forms the cornerstone of management and must be initiated concurrently with pharmacotherapy. Dietary modification targets modifiable purine load and insulin resistance: patients should limit intake of high-purine foods—including red meat, organ meats, shellfish, and yeast extracts—while avoiding fructose-sweetened beverages and excessive alcohol (particularly beer and spirits). Increased consumption of low-fat dairy products, cherries (rich in anthocyanins with uricosuric and anti-inflammatory properties), and plant-based proteins is encouraged. Hydration remains critical; daily fluid intake should exceed 2 L to promote uric acid dilution and reduce nephrolithiasis risk. Weight management is essential: gradual weight loss (0.5–1.0 kg/week) via caloric restriction and aerobic exercise improves insulin sensitivity and reduces uric acid production. However, rapid weight loss or ketogenic diets must be avoided due to ketosis-induced uric acid retention. Patients with hypertension or CKD should adhere strictly to sodium restriction (<2 g/day) and avoid diuretics unless clinically indispensable.

Pharmacologic therapy is indicated for recurrent gout attacks (>2/year), tophi, uric acid nephrolithiasis, or CKD stage ≥3. First-line urate-lowering therapy (ULT) is allopurinol, a xanthine oxidase inhibitor. Initiation at low doses (100 mg/day in normal renal function; 50 mg/day in eGFR <60 mL/min/1.73m²) minimizes hypersensitivity risk, with gradual titration every 2–4 weeks based on serum uric acid monitoring until target is achieved. Febuxostat serves as an alternative in patients intolerant or nonresponsive to allopurinol, particularly those with moderate renal impairment; however, cardiovascular safety requires careful assessment in patients with established ischemic heart disease. For underexcretors (fractional excretion of uric acid <5%), uricosurics—including probenecid (contraindicated in urolithiasis or eGFR <50 mL/min/1.73m²) and lesinurad (used adjunctively with xanthine oxidase inhibitors)—may be considered. Topiroxostat, a newer non-purine xanthine oxidase inhibitor approved in China, offers favorable pharmacokinetics and lower hypersensitivity incidence. During ULT initiation, prophylactic anti-inflammatory therapy (e.g., low-dose colchicine 0.5–0.6 mg once or twice daily for 6 months) is mandatory to prevent acute gout flares triggered by crystal mobilization. NSAIDs or low-dose glucocorticoids may substitute in colchicine-intolerant patients.

Surgical treatment plays a highly selective role and is never indicated for hyperuricemia alone. Indications are exclusively mechanical or structural: large, painful, or ulcerating tophi causing joint deformity, nerve compression (e.g., carpal tunnel syndrome), or functional impairment unresponsive to ≥6 months of optimized ULT. Surgical excision—typically performed under regional anesthesia with meticulous soft-tissue handling—requires concurrent optimization of serum uric acid to <5.0 mg/dL for ≥6 months preoperatively to minimize recurrence. Arthroscopic debridement may be employed for intra-articular tophi with synovitis. Nephrolithiasis necessitates urologic intervention (e.g., extracorporeal shockwave lithotripsy or ureteroscopy) only when stones cause obstruction, infection, or intractable pain; asymptomatic radiolucent uric acid stones are managed medically with urinary alkalinization (target pH 6.2–6.9) and hydration. Surgery does not replace medical therapy; rather, it complements long-term urate control.

Treatment advantages in China reflect integrated clinical infrastructure, regulatory agility, and epidemiologic responsiveness. The National Health Commission’s 2023 Clinical Practice Guidelines for Hyperuricemia and Gout emphasize standardized, tiered care across primary, secondary, and tertiary hospitals, with rheumatology-led multidisciplinary clinics incorporating nephrology, endocrinology, and nutrition support. China’s robust pharmaceutical innovation ecosystem has accelerated approval of domestically developed agents: topiroxostat received NMPA approval in 2021, and novel uricosurics (e.g., dotinurad analogs) are in late-phase trials. Real-world evidence from the China Gout Registry demonstrates superior adherence and target attainment rates (78% at 12 months) in patients managed within designated gout centers versus community care. Furthermore, AI-assisted decision support tools embedded in electronic health records enable dynamic dose titration and flare-risk prediction using longitudinal uric acid trajectories and comorbidity weighting. Traditional Chinese Medicine (TCM) adjuncts—such as Tongfengling granules (containing Smilax glabra and Atractylodes macrocephala)—are prescribed per integrated protocols for their demonstrated anti-inflammatory and mild uricosuric effects, though always as adjuncts to evidence-based ULT.

Recovery and long-term management hinge on patient empowerment and structured follow-up. Serum uric acid must be monitored every 2–4 weeks during ULT titration, then quarterly once stable. Renal function, liver enzymes, and complete blood count require biannual assessment. Patients should maintain a symptom diary documenting flares, medication adherence, dietary deviations, and precipitants (e.g., trauma, illness). Annual dual-energy CT (DECT) scanning is recommended for tophus burden quantification in refractory cases. Lifestyle counseling must be repeated at each visit, emphasizing that hyperuricemia is a chronic, relapsing condition requiring lifelong surveillance—not episodic intervention. Psychosocial support addresses stigma associated with gout and fosters self-efficacy. Finally, vaccination against influenza and pneumococcus is advised given the heightened infection risk in patients with chronic inflammation and/or immunomodulatory therapy. With comprehensive, individualized, and sustained intervention, hyperuricemia is not merely controllable—it is preventable in its most destructive manifestations.